Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus CAPEOX and radiation in MSS locally advanced rectal cancer
NCT05216653Phase 2Completed
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in rectal adenocarcinoma, sponsored by Sir Run-Run Shaw Hospital. Started Apr 2022; status: completed.
02
Drugs
envafolimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05216653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216653.